Gene expression analysis of matched ovarian primary tumors and peritoneal metastasis

• Main Authors: Malek, J.A, Martinez, A, Mery, E, Ferron, G, Huang, R, Raynaud, C, Jouve, E, Thiery, J.-P, Querleu, D, Rafii, A
• Other Authors: CANCER SCIENCE INSTITUTE OF SINGAPORE
• Format: Article
• Published: 2020
• Subjects: 1 (1 cyano 1 methylethyl) 3 methyl 8 (3 quinolinyl)imidazo[4,5 c]quinolin 2(1h,3h) one; 4 diallylaminomethylene 1,3,4,7,10,11,12,13,14,15,16,17 dodecahydro 6 hydroxy 1 methoxymethyl 10,13 dimethyl 3,7,17 trioxo 2 oxacyclopenta[a]phenanthren 11 yl acetate; [1 (4 oxo 8 phenyl 4h 1 benzopyran 2 yl)morpholinio]methoxysuccinylarginylglycylaspartylserine acetate; buparlisib; carboplatin; crizotinib; DNA; interleukin 6; Janus kinase; mitogen activated protein kinase kinase kinase 4; paclitaxel; phosphatidylinositol 3 kinase; RNA; STAT protein; tocilizumab; vemurafenib; xl 147; adjuvant therapy; article; clinical article; copy number variation; enzyme activation; enzyme inhibition; female; gene expression; gene expression profiling; gene targeting; haplotype map; human; human tissue; immune response; multiple cycle treatment; nucleotide sequence; ovary cancer; peritoneum metastasis; personalized medicine; signal transduction; transcriptomics; Female; Gene Expression Profiling; Humans; Ovarian Neoplasms; Peritoneal Neoplasms; Prognosis
• Online Access: https://scholarbank.nus.edu.sg/handle/10635/181608
• Institution: National University of Singapore

10.1186/1479-5876-10-121